Search Results
Adam Brufsky, MD, PhD: Choices of Therapy
Treating Bone Mets with Adam Brufsky, MD, PhD
Adam Brufsky, MD, PhD: Expectations of Therapy in Breast Cancer
Adam Brufsky, MD, PhD, discusses the issue of resistance to HER2-targeted therapy
Adam Brufsky, MD, PhD: Clinical Trial Data Supporting These Choices
Adam Brufsky, MD, PhD, elaborates on the clinical implications of DESTINY-Breast01 from SABCS 2020
Dr. Brufsky on Challenges in Breast Cancer
Adam Brufsky, MD, PhD, discusses results from the Phase III NALA study presented at SABCS 2020
AC versus TaxAC in High-Risk HER2-Negative MBC
Adam Brufsky, MD, PhD, describes the treatment landscape of HER2+ metastatic breast cancer
Considerations When Treating With Hormone Therapy
Dr. Brufsky Discusses Reasons to Use Biosimilars in Oncology